Analysts at FinnCap began coverage on shares of ImmuPharma (LON:IMM) in a report issued on Tuesday. The brokerage set a “buy” rating and a GBX 237 ($3.19) price target on the stock. FinnCap’s price objective indicates a potential upside of 52.90% from the company’s current price.
Other analysts have also issued research reports about the stock. Northland Securities reiterated a “buy” rating and set a GBX 181 ($2.44) price target on shares of ImmuPharma in a research report on Wednesday, October 4th. Northland Capital Partners reiterated a “buy” rating and set a GBX 181 ($2.44) price target on shares of ImmuPharma in a research report on Thursday, September 21st.
Shares of ImmuPharma (LON IMM) opened at GBX 158.25 ($2.13) on Tuesday. ImmuPharma has a 1-year low of GBX 36 ($0.48) and a 1-year high of GBX 175.35 ($2.36).
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.